New Therapy Approved for Hodgkin Lymphoma Patients

We want to share some exciting news with you about FDA approval of a therapy for classical Hodgkin lymphoma. What’s more, this approval may have positive ramifications beyond this important news.
The approved therapy, pembrolizumab (Keytruda®), is an immune checkpoint inhibitor that helps the patient’s immune system more readily recognize and attack cancer cells.
While Hodgkin lymphoma is considered one of the most curable cancers, this newly approved therapy is for patients who have relapsed after current therapies, and who have limited treatment options.
Approval of pembrolizumab for people with classical Hodgkin lymphoma also reinforces the hope that immunotherapy will prove effective in fighting a wide variety of cancers. In fact, The Leukemia & Lymphoma Society (LLS) is currently funding research on the benefits of this same immunotherapy for patients with non-Hodgkin lymphoma.
Ongoing research into new treatments and advances like this is paving the way for a promising future.
Click image for more details.

Leave a Reply

Your email address will not be published. Required fields are marked *